Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda

Guinevere Q. Lee, David Bangsberg, Conrad Muzoora, Yap Boum, Jessica H. Oyugi, Nneka Emenyonu, John Bennett, Peter W. Hunt, David Knapp, Chanson J. Brumme, P. Richard Harrigan, Jeffrey N. Martin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in resource-limited settings where there are fewer regimen choices and limited pretherapy/posttherapy resistance testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and assessed its virologic consequences after antiretroviral therapy initiation. We sequenced the HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-naive participants of the Uganda AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list. Posttreatment viral load data were available for both populations. Overall TDR prevalence was 7% (Kampala) and 3% (Mbarara) with no significant time trend. There was a slight but statistically nonsignificant trend indicating that the presence of TDR was associated with a worse treatment outcome. Virologic suppression (≤400 copies/ml within 6 months posttherapy initiation) was achieved in 87% and 96% of participants with wildtype viruses versus 67% and 83% of participants with TDR (AMU, MBA p=0.2 and 0.1); time to suppression (log-rank p=0.3 and p=0.05). Overall, 85% and 96% of study participants achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half still achieved suppression; the presence of pretherapy K103N while on nevirapine and fewer active drugs in the first regimen were most often observed with failures. The majority of patients benefited from the local HIV care system even without resistance monitoring. Overall, TDR prevalence was relatively low and its presence did not always imply treatment failure.

Original languageEnglish (US)
Pages (from-to)896-906
Number of pages11
JournalAIDS Research and Human Retroviruses
Volume30
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Uganda
Drug Resistance
HIV-1
Nevirapine
Mutation
Viral Load
Treatment Failure
Acquired Immunodeficiency Syndrome
Outcome Assessment (Health Care)
HIV
Viruses

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases
  • Medicine(all)

Cite this

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. / Lee, Guinevere Q.; Bangsberg, David; Muzoora, Conrad; Boum, Yap; Oyugi, Jessica H.; Emenyonu, Nneka; Bennett, John; Hunt, Peter W.; Knapp, David; Brumme, Chanson J.; Harrigan, P. Richard; Martin, Jeffrey N.

In: AIDS Research and Human Retroviruses, Vol. 30, No. 9, 01.09.2014, p. 896-906.

Research output: Contribution to journalArticle

Lee, GQ, Bangsberg, D, Muzoora, C, Boum, Y, Oyugi, JH, Emenyonu, N, Bennett, J, Hunt, PW, Knapp, D, Brumme, CJ, Harrigan, PR & Martin, JN 2014, 'Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda', AIDS Research and Human Retroviruses, vol. 30, no. 9, pp. 896-906. https://doi.org/10.1089/aid.2014.0043
Lee, Guinevere Q. ; Bangsberg, David ; Muzoora, Conrad ; Boum, Yap ; Oyugi, Jessica H. ; Emenyonu, Nneka ; Bennett, John ; Hunt, Peter W. ; Knapp, David ; Brumme, Chanson J. ; Harrigan, P. Richard ; Martin, Jeffrey N. / Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. In: AIDS Research and Human Retroviruses. 2014 ; Vol. 30, No. 9. pp. 896-906.
@article{f8b2cba186c64260ab2476b0591bf2e6,
title = "Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda",
abstract = "Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in resource-limited settings where there are fewer regimen choices and limited pretherapy/posttherapy resistance testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and assessed its virologic consequences after antiretroviral therapy initiation. We sequenced the HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-naive participants of the Uganda AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list. Posttreatment viral load data were available for both populations. Overall TDR prevalence was 7{\%} (Kampala) and 3{\%} (Mbarara) with no significant time trend. There was a slight but statistically nonsignificant trend indicating that the presence of TDR was associated with a worse treatment outcome. Virologic suppression (≤400 copies/ml within 6 months posttherapy initiation) was achieved in 87{\%} and 96{\%} of participants with wildtype viruses versus 67{\%} and 83{\%} of participants with TDR (AMU, MBA p=0.2 and 0.1); time to suppression (log-rank p=0.3 and p=0.05). Overall, 85{\%} and 96{\%} of study participants achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half still achieved suppression; the presence of pretherapy K103N while on nevirapine and fewer active drugs in the first regimen were most often observed with failures. The majority of patients benefited from the local HIV care system even without resistance monitoring. Overall, TDR prevalence was relatively low and its presence did not always imply treatment failure.",
author = "Lee, {Guinevere Q.} and David Bangsberg and Conrad Muzoora and Yap Boum and Oyugi, {Jessica H.} and Nneka Emenyonu and John Bennett and Hunt, {Peter W.} and David Knapp and Brumme, {Chanson J.} and Harrigan, {P. Richard} and Martin, {Jeffrey N.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1089/aid.2014.0043",
language = "English (US)",
volume = "30",
pages = "896--906",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda

AU - Lee, Guinevere Q.

AU - Bangsberg, David

AU - Muzoora, Conrad

AU - Boum, Yap

AU - Oyugi, Jessica H.

AU - Emenyonu, Nneka

AU - Bennett, John

AU - Hunt, Peter W.

AU - Knapp, David

AU - Brumme, Chanson J.

AU - Harrigan, P. Richard

AU - Martin, Jeffrey N.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in resource-limited settings where there are fewer regimen choices and limited pretherapy/posttherapy resistance testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and assessed its virologic consequences after antiretroviral therapy initiation. We sequenced the HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-naive participants of the Uganda AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list. Posttreatment viral load data were available for both populations. Overall TDR prevalence was 7% (Kampala) and 3% (Mbarara) with no significant time trend. There was a slight but statistically nonsignificant trend indicating that the presence of TDR was associated with a worse treatment outcome. Virologic suppression (≤400 copies/ml within 6 months posttherapy initiation) was achieved in 87% and 96% of participants with wildtype viruses versus 67% and 83% of participants with TDR (AMU, MBA p=0.2 and 0.1); time to suppression (log-rank p=0.3 and p=0.05). Overall, 85% and 96% of study participants achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half still achieved suppression; the presence of pretherapy K103N while on nevirapine and fewer active drugs in the first regimen were most often observed with failures. The majority of patients benefited from the local HIV care system even without resistance monitoring. Overall, TDR prevalence was relatively low and its presence did not always imply treatment failure.

AB - Few reports have examined the impact of HIV-1 transmitted drug resistance (TDR) in resource-limited settings where there are fewer regimen choices and limited pretherapy/posttherapy resistance testing. In this study, we examined TDR prevalence in Kampala and Mbarara, Uganda and assessed its virologic consequences after antiretroviral therapy initiation. We sequenced the HIV-1 protease/reverse transcriptase from n=81 and n=491 treatment-naive participants of the Uganda AIDS Rural Treatment Outcomes (UARTO) pilot study in Kampala (AMU 2002-2004) and main cohort in Mbarara (MBA 2005-2010). TDR-associated mutations were defined by the WHO 2009 surveillance mutation list. Posttreatment viral load data were available for both populations. Overall TDR prevalence was 7% (Kampala) and 3% (Mbarara) with no significant time trend. There was a slight but statistically nonsignificant trend indicating that the presence of TDR was associated with a worse treatment outcome. Virologic suppression (≤400 copies/ml within 6 months posttherapy initiation) was achieved in 87% and 96% of participants with wildtype viruses versus 67% and 83% of participants with TDR (AMU, MBA p=0.2 and 0.1); time to suppression (log-rank p=0.3 and p=0.05). Overall, 85% and 96% of study participants achieved suppression regardless of TDR status. Surprisingly, among the TDR cases, approximately half still achieved suppression; the presence of pretherapy K103N while on nevirapine and fewer active drugs in the first regimen were most often observed with failures. The majority of patients benefited from the local HIV care system even without resistance monitoring. Overall, TDR prevalence was relatively low and its presence did not always imply treatment failure.

UR - http://www.scopus.com/inward/record.url?scp=84906919930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906919930&partnerID=8YFLogxK

U2 - 10.1089/aid.2014.0043

DO - 10.1089/aid.2014.0043

M3 - Article

C2 - 24960249

AN - SCOPUS:84906919930

VL - 30

SP - 896

EP - 906

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 9

ER -